2 independent meta-analyses suggested that drug-eluting stents (DES), despite being more effective than bare-metal stents (BMS) in reducing restenosis, increase mortality due to very late thrombosis (1). However, this was no longer confirmed by a plethora of randomized controlled trials (RCTs) and network meta-analyses (NMAs), demonstrating contemporary DES to be not only safe, but even safer than BMS (2) . Unquestionably, advancements in DES 
recommends refraining from over-interpretation when considering how they position themselves in the ranking. Conversely, the number of randomized patients in other nodes is so high (>10,000) that one may legitimately suspect some statistically significant differences to be the reflection of overpowering rather than the signal of a truly remarkable effect. When interpreting the results, the reader should also consider that a NMA assumes all patients to come from RCTs with a very low degree of variability, which is obviously not true.
These limitations taken into account, the DES that more frequently (n ¼ 6) were found to significantly 
